RGEN Repligen Corporation
RGEN Repligen Corporation
Healthcare · Medical Instruments & Supplies
Desk view
Market read
POC $164.20 · VWAP $146.02 · +20.1% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 related campaign
RGEN Price Structure
Loading timeframes…
Peers
Every watchlist RGEN belongs to, members best 30-day change first — RGEN highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
Reported the quarter ending 2026-06-30: revenue $204M, diluted EPS $0.09, net income $5M (SEC filing). Across the print the stock moved +7.8% (close before → first close after).
full note →Against street estimates
How RGEN's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about RGEN from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 1 day ago · Oct 16
- Repligen Corp (RGEN) Stock Up 3.4% but GF Value Says Overvalued
- Repligen Stock Price | RGEN Stock Quote, News, and History | Markets Insider
- RGEN Stock Price Quote | Morningstar
- Repligen Corporation Stock (RGEN) - Quote Nasdaq- MarketScreener Canada
- Repligen projects $813M-$834M 2026 revenue amid BioLife deal and raised $2.03-$2.09 EPS (NASDAQ:RGEN) | Seeking Alpha
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
RGEN research tape
37 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.